IND application submitted for GTB-5550 TriKE for B7-H3 expressing solid tumor cancers
“The IND for GTB-5550 represents another NK cell engager we plan to move into clinical development and a tremendous accomplishment for the company”, said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “As we continue actively enrolling the Phase 1 trial with GTB-3650 in myeloid blood cancer, we expect the next data readout in 1H 2026 could provide potential evidence of clinical activity. Initiation of a Phase 1 basket trial with GTB-5550 for multiple solid tumors is planned for 2026. We look forward to applying the clinical learnings from the GTB-3650 study to help inform the GTB-5550 program, which targets a patient population with B7-H3 expressing solid tumors that is orders of magnitude larger than the myeloid blood cancer patient population.” The global market for B7-H3 expressing solid tumor cancers accounts for a portion of the estimated $362 billion global solid tumor cancers market (according to Data Bridge Market Research). B7-H3 expressing solid tumor cancers are estimated to account for a significant portion of solid tumor cancers.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000